The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Braunstein Scott since 2016.
This trader's CIK number is 1643875.
At the time of last reporting, Braunstein Scott was the CHAIRMAN AND CEO of Marinus Pharmaceuticals, Inc.. (stock ticker symbol MRNS).
Also see all insider trading activities at Marinus Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | MRNS | 5,933 | $6,526 | 0 | $0 | 0 | $0 |
| 2024 | MRNS | 0 | $0 | 23,995 | $131,512 | 50,000 | $214,000 |
| 2023 | MRNS | 0 | $0 | 6,443 | $61,512 | 0 | $0 |
| 2019 | MRNS | 100,000 | $125,000 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2017 | PCRX | 0 | $0 | 768 | $33,270 | 0 | $0 |
| 2016 | PCRX | 2,000 | $117,840 | 0 | $0 | 0 | $0 |
1. Marinus Pharmaceuticals, Inc. (MRNS)
2. Pacira Biosciences, Inc. (PCRX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-08-14 | MRNS | Buy | 5,933 | 1.10 | 6,526 |
| 2024-08-05 | MRNS | Sale | 12,145 | 1.13 | 13,723 |
| 2024-03-27 | MRNS | Option Ex | 50,000 | 4.28 | 214,000 |
| 2024-02-16 | MRNS | Sale | 11,850 | 9.94 | 117,789 |
| 2023-08-08 | MRNS | Sale | 30 | 8.94 | 268 |
| 2023-08-07 | MRNS | Sale | 6,413 | 9.55 | 61,244 |
| 2019-12-13 | MRNS | Buy | 100,000 | 1.25 | 125,000 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-06-05 | PCRX | Sale | 768 | 43.32 | 33,270 |
| 2016-01-29 | PCRX | Buy | 2,000 | 58.92 | 117,840 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Braunstein Scott (CHAIRMAN AND CEO of Marinus Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.